A phase 1, open-label, randomized drug–drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies

Bilal Tariqa Clinical Pharmacology, BeiGene USA, Inc, Fulton, MD, USACorrespondence[email protected]

https://orcid.org/0000-0003-1409-9489 View further author information

Ying C. Oub Clinical Pharmacology, BeiGene USA, Inc, San Mateo, CA, USAView further author information

Jennifer C. Sternb Clinical Pharmacology, BeiGene USA, Inc, San Mateo, CA, USAView further author information

Vaibhav Mundrab Clinical Pharmacology, BeiGene USA, Inc, San Mateo, CA, USAView further author information

Nicole Wong Dooc Department of Hematology, Concord Repatriation General Hospital, Concord, Australia;d Concord Clinical School, University of Sydney, Sydney, AustraliaView further author information

Patricia Walkere Department of Hematology, Peninsula Health and Peninsula Private Hospitals, Frankston, AustraliaView further author information

Katharine L. Lewisf Department of Haematology, Sir Charles Gairdner Hospital and Linear Clinical Research, Nedlands, AustraliaView further author information

Chester Ling Biostatistics, BeiGene, Ltd, Emeryville, CA, USAView further author information

William Novotnyh Clinical Development, Hematology, BeiGene USA, Inc, San Mateo, CA, USAView further author information

Srikumar Sahasranamanb Clinical Pharmacology, BeiGene USA, Inc, San Mateo, CA, USAView further author information

Stephen Opati Clinical Hematology, Monash Health and Monash University, Clayton, Australia

https://orcid.org/0000-0002-0308-6458 View further author information

show all

A phase 1, open-label, randomized drug–drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies

GLAL-2022-0792-File008.docx

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

A phase 1, open-label, randomized drug–drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies

GLAL-2022-0792-File008.docx

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date